SE0002232D0 - antioxidant - Google Patents
antioxidantInfo
- Publication number
- SE0002232D0 SE0002232D0 SE0002232A SE0002232A SE0002232D0 SE 0002232 D0 SE0002232 D0 SE 0002232D0 SE 0002232 A SE0002232 A SE 0002232A SE 0002232 A SE0002232 A SE 0002232A SE 0002232 D0 SE0002232 D0 SE 0002232D0
- Authority
- SE
- Sweden
- Prior art keywords
- tyrosyl
- gly
- disease
- group
- analogues
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 230000003078 antioxidant effect Effects 0.000 title 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 125000002711 cysteinyl group Chemical group 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 abstract 1
- -1 serinyl Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Glutathione analogues are disclosed. These have Formula (I): X-Glu-Y-Gly-Z, wherein Glu is glutamyl or gamma -glutamyl, and Gly is glycine or glycyl, X is selected from the group consisting of H-; (O-R)tyrosyl; biotinyl-(O-R)tyrosyl; anthraniloyl-(O-R)tyrosyl; (O-R) tyrosyl-aminohexanoyl-; and 5-alkoxy tryptophyl-; Y is selected from the group consisting of cysteinyl, serinyl, methionyl or selenocysteinyl; and Z is selected from the group consisting of -H; (O-R)tyrosine; and aminohexanoyl-(O-R)tyrosine, and wherein each amino acids can be either a L- or a D- enantiomer; the peptide bonds may optionally be methylated, and the carboxyl groups are free acids, amides, or mono- or di-alkyl esters, and R is selected from alkyl, alkenyl, aryl and aryl containing one or several heteroatoms in the ring(s); with the provisio that X is not H when Y is L-cysteinyl and Gly is L-glycyl. Glutathione analogues for use as antioxidants, e.g. in cosmetics and pharmaceutical compositions, use of the gluthathione analogues for the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a disease or disorder associated with oxidative degeneration of cells, such as Alzheimer's disease or Parkinson's disease, and a method of such treatment, are also described.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002232A SE0002232D0 (en) | 2000-06-15 | 2000-06-15 | antioxidant |
| PCT/SE2001/001351 WO2001096369A1 (en) | 2000-06-15 | 2001-06-14 | Gluthione analogues and their use as antioxidants |
| AU2001274745A AU2001274745A1 (en) | 2000-06-15 | 2001-06-14 | Gluthione analogues and their use as antioxidants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002232A SE0002232D0 (en) | 2000-06-15 | 2000-06-15 | antioxidant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0002232D0 true SE0002232D0 (en) | 2000-06-15 |
Family
ID=20280094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0002232A SE0002232D0 (en) | 2000-06-15 | 2000-06-15 | antioxidant |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001274745A1 (en) |
| SE (1) | SE0002232D0 (en) |
| WO (1) | WO2001096369A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070037848A1 (en) * | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
| KR101592068B1 (en) | 2013-11-08 | 2016-02-05 | 순천향대학교 산학협력단 | Marker and Kit for Diagnosising and Distingushing Aspirin exacerbated respiratory diseases and Aspirin tolerant asthma |
| JP2025505052A (en) | 2021-01-24 | 2025-02-20 | デイヴィッド フォレスト マイケル | Inhibitors of ATP synthase - cosmetic and therapeutic uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3568775D1 (en) * | 1984-06-22 | 1989-04-20 | Nattermann A & Cie | S-(carbamoyl-phenylselenyl) derivatives of glutathion and of amino mercaptocarboxylic acids, process for their preparation and pharmaceutical preparations containing them |
| US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
-
2000
- 2000-06-15 SE SE0002232A patent/SE0002232D0/en unknown
-
2001
- 2001-06-14 WO PCT/SE2001/001351 patent/WO2001096369A1/en active Application Filing
- 2001-06-14 AU AU2001274745A patent/AU2001274745A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001096369A1 (en) | 2001-12-20 |
| AU2001274745A1 (en) | 2001-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL122754A0 (en) | Cyclosporin derivatives their preparation and pharmaceutical compositions containing them | |
| TR199701071T2 (en) | Compounds and compositions for the delivery of the active substance. | |
| NZ333609A (en) | Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells | |
| ES2160485A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| HK1021824A1 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| ATE206716T1 (en) | CYCLIC PRODUCERS COMPOUNDS OF PEPTIDES AND PEPTIDE-NUCLIC ACIDS WITH IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | |
| ATE513847T1 (en) | BIOACTIVE PEPTIDES | |
| BR9910639A (en) | Anti-angiogenic drugs comprising peptide | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| RU2223970C2 (en) | Obesity treatment | |
| ATE14226T1 (en) | CYCLIC OCTAPEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AND PROCESSES FOR THE MANUFACTURE THE SAME AND THEIR USE. | |
| ATE213499T1 (en) | PEPTIDE ANALOGUES OF HUMAN BASIC MYELIN PROTEIN WITH SUBSTITUTION AT POSITION 91 FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| CY1107990T1 (en) | TRIPeptides and TRIPeptides derivatives for the treatment of neurodegenerative diseases | |
| TWI415628B (en) | Compositions containing peptides with non-natural amino acids and methods of use | |
| FR2846883B1 (en) | COSMETIC COMPOSITION COMPRISING, AS ACTIVE INGREDIENT, AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE | |
| SE0002232D0 (en) | antioxidant | |
| IL104574A (en) | N-[[3,4-dichlorophenyl)amino] carbonyl]-2,3-dihydro benzofuran-5-sulfonamide its preparation and antitumor compositions containing it and uses thereof | |
| AU2003292326A1 (en) | Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser | |
| GB1533077A (en) | 4-substituted enkephalin derivatives | |
| DE69430416D1 (en) | Amino acid compositions for the treatment of infections | |
| DE50114335D1 (en) | LH-RH ANTAGONISTS, THEIR PREPARATION AND THEIR USE AS DRUGS | |
| DE3467581D1 (en) | Gastric secretion inhibiting peptide derivatives, process for their preparation and medicines containing them | |
| DE69500490D1 (en) | Medicinal preparations that relax smooth muscle | |
| US7375085B1 (en) | Melanocyte-stimulating hormone inhibitors | |
| ES2088239T3 (en) | NEW PEPTIDIC DERIVATIVES, PREPARATION PROCEDURE AND APPLICATION AS DRUGS OF THESE NEW DERIVATIVES. |